Rarely has any big pharma-biotech joint venture been so strategic – and so generous – in grafting existing expertise onto a start-up, from the ground up. And Bayer has gained some welcome protection against the distractions of the company’s recent – and controversial – diversification into lines of business beyond patented medicines.
Jim Burns, CEO of Casebia Therapeutics, expects the company’s first Investigational New Drug (IND) filing with the FDA to...